Biotechnology European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer’s Drug Lecanemab Why Is Biogen Stock Falling Friday? – Biogen (NASDAQ:BIIB) Read more
Biotechnology Biogen’s Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers – Biogen (NASDAQ:BIIB) Read more
Biotechnology Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says – Biogen (NASDAQ:BIIB) Read more
Biotechnology Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer’s, Shifts Focus On Newer Medicines – Biogen (NASDAQ:BIIB) Read more